Tulip Sponsors FDA Study for COVID-19 Patients
Posted September 09, 2020 in Uncategorized | 1 minute read
Just published in the Journal of Current Medical Research and Opinion
SDARTs faculty member, Robert W. Alexander, MD, DDS, is the Principle Investigator on a first-in-human clinical trial using AD cSVF to treat post-COVID 19 survivors suffering residual lung damage.
Many moderate to severe post-COVID 19 survivors experience compromised lung function. As a proposed solution, adipose-derived cellular stromal vascular fraction (AD cSVF) may be effective in reversing residual damage to the lungs and gas exchange functions.
Tulip Medical is grateful to have the opportunity to sponsor this trial and provide surgical instrumentation for it.
